

July 31, 2025



## XORTX Announces USD \$114,500 Private Placement

CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("**XORTX**" or the "**Company**") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces a non-brokered private placement to raise up to USD \$114,500 through the issuance of up to 156,849 common share units ("**Units**") of the Company at a price of USD \$0.73 per unit (the "**Offering**"). Each Unit will be comprised of one common share and one common share purchase warrant (a "**Warrant**"). Each Warrant will entitle the holder, on exercise, to purchase one additional common share in the capital of the Company, at a price of USD \$1.20 per Warrant until the close of business on the day which is 60 months from the date of issuance of the Units, provided, however, that if the closing price of the common shares on the Nasdaq is greater than USD \$2.00 for 10 or more consecutive trading days, the Warrants will be accelerated and the Warrants will expire on the 30<sup>th</sup> business day following the date of such notice.

Allen Davidoff, CEO of XORTX stated, "With additional interest in the LIFE offering (see news release of June 26 and July 22, 2025) from non-Canadian investors, XORTX has undertaken this small private placement to accommodate these subscribers."

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The closing date of the Offering is expected to occur on or about August 5, 2025, or such later date or dates as the Company may determine, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including approval from the TSX Venture Exchange. The Company intends to use the proceeds of the Offering for gout programs, general corporate and working capital purposes. All securities issued under the Offering will be subject to a four month and one day "hold period" under applicable Canadian securities legislation.

### About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XR<sub>x</sub>-026 program for the treatment of gout; 2) XR<sub>x</sub>-008 program for ADPKD; and 3) XR<sub>x</sub>-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XR<sub>x</sub>-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance

products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at [www.xortx.com](http://www.xortx.com).

For more information, please contact:

Allen Davidoff, CEO

[adavidoff@xortx.com](mailto:adavidoff@xortx.com) or +1 403 455 7727

Nick Rigopoulos, Director of Communications

[nick@alpineequityadv.com](mailto:nick@alpineequityadv.com) or +1 617 901 0785

*Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.*

### **Forward Looking Statements**

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, the use of the net proceeds of the Offering; the terms of the Offering; the timing and completion of the Offering; and the receipt of regulatory, stock exchange and other required approvals in connection with the Offering, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading "Risk Factors" in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, [www.sec.gov](http://www.sec.gov) (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on [www.sedarplus.ca](http://www.sedarplus.ca).



Source: XORTX Therapeutics Inc.